Herpes zoster as an immune reconstitution illness after initiation of mixture antiretroviral therapy in patients with human immunodeficiency virus kind-1 infection. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count stay risk factors for cytomegalovirus illness in patients receiving highly active antiretroviral therapy. Plasma cytomegalovirus (CMV) DNA load predicts CMV illness and survival in AIDS patients. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to extremely active antiretroviral therapy. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after extremely lively antiretroviral therapy. Valganciclovir therapy for immune restoration uveitis complicated by macular edema. Intravitreal cidofovir (HPMPC) remedy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. High-dose (2000-microgram) intravitreous ganciclovir within the treatment of cytomegalovirus retinitis. Oral ganciclovir as upkeep treatment for cytomegalovirus retinitis in patients with AIDS. Oral ganciclovir for patients with cytomegalovirus retinitis handled with a ganciclovir implant. Syntex Cooperative Oral Ganciclovir Study Group.
发表于 2024-9-16 04:43